Polymer-protein-enhanced fluoroimmunoassay for prostate-specific antigen.
Prostate-specific antigen (PSA) is a serum glycoprotein overproduced in prostate cancer, the total of which is comprised of two major forms, free and complexed. The common method for measuring of PSA is an Enzyme-linked immunosorbent assay (ELISA). Limits of detection using commercial PSA ELISA kits for free and total PSA were determined in our laboratory to be 1 and 10 ng/mL, respectively. A value of 0.10 was obtained for the free to total PSA ratio, a ratio of 0.25 being indicative of prostate cancer. A possible improvement in the sensitivity and detection limits of free and total PSA may be achieved by the ALYGNSA system (Clarizia et al., Anal Bioanal Chem 393:1531-1538, 2009). This fluorescent assay system employed a selective polymer biolinker system proven to enhance primary antibody orientation. Using this system, free and total PSA detection limits of 0.13 and 0.63 ng/mL, respectively, were realized. This amounted to an 8- and 15-fold improvement in detection limits for free and total PSA, respectively. A free to total PSA ratio of 0.20 was maintained in this study and may be useful for definitive diagnosis of prostate, as well as, other cancers.
Mackness
Brian C
BC
Biochemistry Program, Department of Chemistry, College of Arts and Sciences, University of Massachusetts Lowell, One University Avenue, Lowell, MA 01854, USA.
Chourb
Sinang
S
Farris
Leslie R
LR
McDonald
Melisenda J
MJ
D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D015200:Fluoroimmunoassay / Q000379:methods*; D006801:Humans; D057230:Limit of Detection; D008297:Male; D011108:Polymers / Q000737:chemistry; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*
D011108:Polymers; D017430:Prostate-Specific Antigen